Aslan Pharmaceuticals (ASLN) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aslan Pharmaceuticals has initiated voluntary liquidation for its main operating subsidiary after a strategic review, leading to the termination of all employees. The company, facing delisting from the Nasdaq due to non-compliance with listing requirements, has appointed Quantuma (Singapore) as the liquidator to explore strategic alternatives for its key assets, eblasakimab and farudodstat, while also preparing to liquidate under Cayman law.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.